Coherus Oncology (CHRS) EBITDA Margin Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) EBITDA Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9,942.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 530.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1,211.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 7,794.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | -8,481.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,481.00 |
| Dec 31, 2025 | -24,636.00 |
| Sep 30, 2025 | -20,603.00 |
| Jun 30, 2025 | -37,042.00 |
| Mar 31, 2025 | -46,329.00 |
| Dec 31, 2024 | -53,297.00 |
| Sep 30, 2024 | -73,448.00 |
| Jun 30, 2024 | -35,730.00 |
| Mar 31, 2024 | -273,549.00 |
| Dec 31, 2023 | -9,016.00 |
| Sep 30, 2023 | -7,261.00 |
| Jun 30, 2023 | -10,697.00 |
| Mar 31, 2023 | -24,403.00 |
| Dec 31, 2022 | -14,990.00 |
| Sep 30, 2022 | -22,352.00 |
| Jun 30, 2022 | -10,612.00 |
| Mar 31, 2022 | -8,987.00 |
| Jun 30, 2020 | 409,371.00 |
| Mar 31, 2020 | 4.50 Mn |
| Dec 31, 2019 | 874,015.00 |